Aignostics receives 14 million euros

The spin-off from Charité in Berlin has thus successfully completed its Series A financing round.

In the end, at least according to Aignostics itself, the planned Series A financing round was even oversubscribed. The start-up, a spin-off from Charité in Berlin, was able to raise 14 million euros. Venture capitalist Wellington Partners led the round. The existing investors Boehringer Ingelheim Venture Fund (BIVF), the VC Fonds Technologie II managed by IBB Ventures and the High-Tech Gründerfonds (HTGF) also participated. The Carma Fund, initiated by Ascenion, also joined the round.

Aignostics develops artificial intelligence (AI)-based models for its pharmaceutical and biotech clients. These are intended to provide new insights into the disease biology of tissue samples. While pathologists can only interpret individual tissue samples qualitatively, they need to analyze large data sets in depth, which the start-up wants to do with its technology. According to the company, the AI models cover the most important tissue staining technologies. This will accelerate research.

"With this new financing round, we want to further expand our presence and our team," says Viktor Matyas, CEO and co-founder of Aignostics. "In particular, we will place a stronger focus on the US market, where we have been active since the beginning of the year."

Aignostics started in 2018 in the Digital Health Accelerator Program of the Berlin Institute of Health (BIH), based on joint research with Charité in Berlin. Aignostics was spun off at the beginning of 2020. To date, the start-up says it has raised almost 20 million euros and has offices in Berlin and Boston.